Epidemiology of Type 2 Diabetes Mellitus

2 型糖尿病的流行病学

• 批准号: 6640213
• 负责人: RICHARD P DONAHUE
• 金额: $ 58.63万
• 依托单位: STATE UNIVERSITY OF NEW YORK AT BUFFALO
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2005-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6640213
• 关键词: antibody; biomarker; blood chemistry; cell adhesion molecules; clinical research; cytoskeletal proteins; disease /disorder etiology; disease /disorder proneness /risk; epidemiology; glutamate decarboxylase; human middle age (35-64); human subject; immune system; inflammation; interleukin 6; longitudinal human study; noninsulin dependent diabetes mellitus; phenotype; phlebotomy; questionnaires; radioimmunoassay; selectins; tumor necrosis factor alpha; vascular endothelium

We propose to comprehensively evaluate a series of inflammatory, antigenic, and endothelial biomarkers for type 2 diabetes mellitus among participants in the Western New York Study. We will recall nearly 3000 cohort members and identify converters to type 2 DM. Using a case-control approach, we will test the following Specific Aims: 1) determine if biomarkers of chronic inflammation including CRP, TNFalpha, IL6 predict incident DM; 2) evaluate whether markers of endothelial function including E-selectin, sICAM1, and sVCAM1 predict DM; and 3) determine if antibodies to glutamic acid decarboxylase (GAD) and IA2 identify a subtype of phenotypic type 2 diabetic persons. We hypothesize that chronic dysregulation of the immune system is a potent predictor of type 2 DM. Cases will be persons who have developed type 2 DM since their baseline examination in 1996- 1998. We propose to control for sex, race, year of baseline exam, and baseline glycemic category in the design phase of the study. Controls will be matched 3:1 to the cases on these variables. Baseline information on risk factors including age, body fat, lipoproteins, physical activity, family history of DM, and smoking will be used to evaluate confounding and effect modification. Baseline plasma samples that will provide the exposure information have been collected, handled, and frozen with a high level of standardization and precision with immediate on-site centrifugation and freezing in our Biological Specimen Bank. The exposures proposed represent state-of-the-art measures and will be assayed in laboratories that serve as CORE labs for several national studies. The proposed research is of great importance due to the epidemic nature of type 2 DM, and the promise that it may be preventable. A better understanding of the etiology of type 2 and a better definition of the "at risk" phenotype can provide health benefits for the millions at risk for acquiring DM.

我们建议在西纽约研究的参与者中全面评估一系列炎症、抗原和内皮生物标志物对2型糖尿病的影响。 我们将召回近3000名队列成员，并确定2型DM的转换者。 使用病例对照方法，我们将测试以下特定目的：1）确定慢性炎症的生物标志物（包括CRP、TNF α、IL 6）是否可预测DM事件; 2）评估内皮功能的标志物（包括E-选择素、sICAM 1和sVCAM 1）是否可预测DM; 3）确定谷氨酸脱羧酶（GAD）和IA 2的抗体是否可识别表型2型糖尿病患者的亚型。 我们假设免疫系统的慢性失调是2型糖尿病的一个有效预测因子。 病例将是自1996- 1998年基线检查以来发展为2型糖尿病的人。 我们建议在研究设计阶段控制性别、人种、基线检查年份和基线血糖类别。 对照组将与这些变量的病例以3：1的比例匹配。 将使用风险因素（包括年龄、体脂、脂蛋白、体力活动、DM家族史和吸烟）的基线信息评价混杂因素和效应修正。 将提供暴露信息的基线血浆样本已在我们的生物样本库中以高水平的标准化和精确度采集、处理和冷冻，并立即进行现场离心和冷冻。 建议的暴露量代表了最先进的措施，将在作为几项国家研究的核心实验室的实验室中进行测定。 由于2型糖尿病的流行性，以及它可能是可预防的，因此拟议的研究非常重要。 更好地了解2型糖尿病的病因和更好地定义“高危”表型可以为数百万有糖尿病风险的人提供健康益处。